Formosa Pharmaceuticals, Inc.
TTWSE:683825.30
TWD
-0.20
(-0.78%)
ISIN
TW0006838006
Return %
Stock
S&P 500
1Y
-16.50
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Li Ko Hsu
- Full Time Employees
- 10
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 57, Fuxing North Road Taipei TP Taiwan 105
- IPO Date
- Aug 13, 2024
- Website
- formosapharma.com
- Similar Companies
- Business
- Formosa Pharmaceuticals, Inc. (6838.TWO) is a clinical-stage biopharmaceutical company that develops novel drug candidates focused on ophthalmology, oncology, and anti-infectives. Founded in 2010 and headquartered at 8F-6, No. 57 Fuxing North Road, Songshan District, Taipei, Taiwan, the company leverages its proprietary APNT nanoparticle formulation platform to enhance pharmacokinetics and bioavailability across its pipeline, including 505(b)(2) applications, biosimilars, and new chemical entities. It primarily operates in Taiwan with global licensing partnerships spanning the United States, Canada, Mexico, Brazil, Europe, Middle East, North Africa, India, Israel, Chile, and other emerging markets. The company's core products and pipeline include APP13007 (clobetasol propionate ophthalmic nanosuspension 0.05%), a U.S. FDA-approved treatment for post-operative inflammation and pain following ocular surgery that offers rapid relief with a twice-daily regimen for 14 days; TSY-110 (also known as TSY-0110), an antibody-drug conjugate biosimilar of Roche's Kadcyla (ado-trastuzumab emtansine) co-developed with EirGenix for HER2-positive metastatic and early breast cancer; TSY-210, a broad-spectrum anti-infective targeting nine of the top 22 WHO/CDC priority pathogens including resistant strains; and oncology assets such as TSY-310 (ALM-401), a first-in-class bispecific ADC licensed from Almac Discovery targeting EGFR/ROR1 in solid tumors, alongside earlier-stage programs like APP13002 and MPT0E028. Formosa Pharmaceuticals targets ophthalmologists, cataract patients, breast cancer patients, and those with nosocomial infections, emphasizing differentiated formulations for improved patient outcomes and market access. In recent developments, the company listed on the Taiwan Stock Exchange in August 2025 following prior registration on the Emerging Stock Board; achieved FDA approval for APP13007 in March 2024 with first U.S. shipments in September 2024; expanded APP13007 licensing to partners including Harrow (U.S. commercialization), Apotex (Canada and Mexico), Adalvo (Europe and Brazil), Rxilient (Southeast Asia), Cipla (India and 10 emerging markets), Saval (Chile and eight Latin American markets), Tabuk (MENA), Tzamal (Israel), Cristalia (Brazil), Grand Pharma (Greater China), Medvisis (Switzerland), and DÁVI (Portugal); initiated co-development with Eyenovia for acute dry eye disease; in-licensed ALM-401 from Almac Discovery in May 2025; reported positive Phase 3 top-line results for APP13007 in China (CPN-303); and advanced TSY-110 toward Phase 1 trials.